Description
Tirzepatide (Mounjaro) is a highly effective, once-weekly injectable that provides significant weight loss (up to ~20% over 72 weeks), improves glycemic control in Type 2 diabetes, and reduces cardiovascular risk. By acting as a dual agonist (GIP and GLP-1 receptors), it suppresses appetite, increases satiety, and lowers visceral adipose inflammation, leading to substantial fat loss and improved metabolic health.
Key Benefits of Tirzepatide
- Significant Weight Loss: Clinical trials show consistent, sustained weight reduction. Participants in studies (SURMOUNT trials) experienced significant weight loss at higher doses (10 mg and 15 mg) over 72 weeks.
- Appetite Control and Reduced Cravings: The medication helps manage hunger, leading to better portion control and diminished cravings for food, including sugary or salty snacks.
- Blood Sugar Management: Originally approved for Type 2 diabetes, it improves HbA1c levels, often lowering them more effectively than single-action GLP-1 medications.
- Cardiovascular and Heart Failure Benefits: Studies indicate reduced cardiovascular risk, including better outcomes for patients with heart failure, such as reduced hospitalizations.
- Improved Metabolism: It helps manage lipid levels, lowers blood pressure, and reduces inflammation, contributing to overall better metabolic health.
- Reduced Visceral Fat: It specifically targets, reduces, and improves adipose tissue inflammation, reducing fat around internal organs
Reviews
There are no reviews yet.